Futerman AH - Search Results

1

Emerging therapeutic targets for Gaucher disease.

Vitner EB, Vardi A, Cox TM, Futerman AH. Vitner EB, et al. Among authors: futerman ah. Expert Opin Ther Targets. 2015 Mar;19(3):321-34. doi: 10.1517/14728222.2014.981530. Epub 2014 Nov 21. Expert Opin Ther Targets. 2015. PMID: 25416676 Review.

2

Analysis of glucocerebrosidase activity using N-(1-[14C]hexanoyl)-D-erythroglucosylsphingosine demonstrates a correlation between levels of residual enzyme activity and the type of Gaucher disease.

Meivar-Levy I, Horowitz M, Futerman AH. Meivar-Levy I, et al. Among authors: futerman ah. Biochem J. 1994 Oct 15;303 ( Pt 2)(Pt 2):377-82. doi: 10.1042/bj3030377. Biochem J. 1994. PMID: 7980395 Free PMC article.

3

Phosphatidylcholine synthesis is elevated in neuronal models of Gaucher disease due to direct activation of CTP:phosphocholine cytidylyltransferase by glucosylceramide.

Bodennec J, Pelled D, Riebeling C, Trajkovic S, Futerman AH. Bodennec J, et al. Among authors: futerman ah. FASEB J. 2002 Nov;16(13):1814-6. doi: 10.1096/fj.02-0149fje. Epub 2002 Sep 5. FASEB J. 2002. PMID: 12223447

4

X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease.

Dvir H, Harel M, McCarthy AA, Toker L, Silman I, Futerman AH, Sussman JL. Dvir H, et al. Among authors: futerman ah. EMBO Rep. 2003 Jul;4(7):704-9. doi: 10.1038/sj.embor.embor873. EMBO Rep. 2003. PMID: 12792654 Free PMC article.

5

New directions in the treatment of Gaucher disease.

Futerman AH, Sussman JL, Horowitz M, Silman I, Zimran A. Futerman AH, et al. Trends Pharmacol Sci. 2004 Mar;25(3):147-51. doi: 10.1016/j.tips.2004.01.004. Trends Pharmacol Sci. 2004. PMID: 15019270 Review. No abstract available.

6

Phosphatidylcholine metabolism is altered in a monocyte-derived macrophage model of Gaucher disease but not in lymphocytes.

Trajkovic-Bodennec S, Bodennec J, Futerman AH. Trajkovic-Bodennec S, et al. Among authors: futerman ah. Blood Cells Mol Dis. 2004 Jul-Aug;33(1):77-82. doi: 10.1016/j.bcmd.2004.03.001. Blood Cells Mol Dis. 2004. PMID: 15223015

7

Enhanced calcium release in the acute neuronopathic form of Gaucher disease.

Pelled D, Trajkovic-Bodennec S, Lloyd-Evans E, Sidransky E, Schiffmann R, Futerman AH. Pelled D, et al. Among authors: futerman ah. Neurobiol Dis. 2005 Feb;18(1):83-8. doi: 10.1016/j.nbd.2004.09.004. Neurobiol Dis. 2005. PMID: 15649698

8

Gaucher disease: pathological mechanisms and modern management.

Jmoudiak M, Futerman AH. Jmoudiak M, et al. Among authors: futerman ah. Br J Haematol. 2005 Apr;129(2):178-88. doi: 10.1111/j.1365-2141.2004.05351.x. Br J Haematol. 2005. PMID: 15813845 Free article. Review.

9

Changes in macrophage morphology in a Gaucher disease model are dependent on CTP:phosphocholine cytidylyltransferase alpha.

Kacher Y, Golan A, Pewzner-Jung Y, Futerman AH. Kacher Y, et al. Among authors: futerman ah. Blood Cells Mol Dis. 2007 Jul-Aug;39(1):124-9. doi: 10.1016/j.bcmd.2007.03.005. Epub 2007 May 7. Blood Cells Mol Dis. 2007. PMID: 17482853

10

Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid beta-glucosidase: insights into the mechanism of chemical chaperone action in Gaucher disease.

Brumshtein B, Greenblatt HM, Butters TD, Shaaltiel Y, Aviezer D, Silman I, Futerman AH, Sussman JL. Brumshtein B, et al. Among authors: futerman ah. J Biol Chem. 2007 Sep 28;282(39):29052-29058. doi: 10.1074/jbc.M705005200. Epub 2007 Jul 31. J Biol Chem. 2007. PMID: 17666401 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

269 results

Search Page